Chemotherapy for metastatic non-small-cell lung cancer--can that dog hunt?

David H. Johnson

DOI: https://doi.org/10.1093/JNCI/85.10.766

1993-05-19

Journal of the National Cancer Institute

Abstract:Although no longer the most common cancer diagnosed in the United States, a dubious distinction now credited to breast cancer, bronchogenic carcinoma remains by far the principal cause of cancer-related deaths. Little progress has been made in the management of lung cancer during the past 20 years because of the systemic nature of this carcinoma and the lack of effective therapy other than surgical resection. More than 75% of patients with non-small-cell lung cancer present with unresectable disease, and even those with resectable lesions have a high propensity to experience recurrence with extrathoracic metastases. Unfortunately, an effective systemic therapy for non-small-cell lung cancer does not exist. Indeed, chemotherapy has failed to prove curative in even an occasional patient with metastatic disease. Since chemotherapy regimens used to treat metastatic non-small-cell lung cancer have no curative potential, what can one reasonably expect from them? An improvement in a patient's quality of life or a prolongation in survival would make therapy warranted. Presumably, a prolongation of life would be accompanied by a reduction in tumor-related symptoms, although this is not necessarily the case. Does chemotherapy improve the survival of non-small-cel l lung cancer patients with metastatic disease? In this issue of the Journal, Cartei et al. describe the results of a randomized phase III trial in which 102 patients with metastatic nonsmall-cell lung cancer received either supportive care or a cisplatin-based chemotherapy regimen plus supportive care (/). Supportive care consisted of analgesics, an antitussive, antibiotics, steroids, palliative radiotherapy, and the relief of increased intracranial pressure. Patients given combination chemotherapy survived a median of 8.5 months compared with just 4 months for those randomly assigned to receive supportive care alone, a difference that has high statistical significance (P<.0001). This observation is encouraging, especially because it is not the first study to demonstrate an improvement in the median survival of patients with stage IV non-small-cell lung cancer treated with chemotherapy. A well-designed Canadian trial of similar size (2) also demonstrated a doubling of the median survival for patients receiving chemotherapy. Does this mean that patients with stage IV non-small-cel l lung cancer routinely benefit from chemotherapy? Unfortunately, the answer is no. Other investigators (3-6) have conducted well-designed randomized studies with negative results.